Evaluating Urine Tumor DNA Using the UroAmp Test to Reduce Cystoscopy Frequency for High-Risk Non-Muscle Invasive Bladder Cancer
Led by Lahey Clinic · Updated on 2026-11-03
56
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of urine tumor DNA utDNA as a marker for non-muscle invasive bladder cancer NMIBC to identify patients who might benefit from less frequent cystoscopy surveillance. This diagnostic trial aims to improve monitoring methods for those with high-risk bladder cancer by comparing standard care with a de-intensified surveillance approach.
Participants are randomly assigned to one of two groups a de-intensified surveillance group that undergoes fewer cystoscopy procedures guided by the UroAmp Test, a non-invasive genomic urine test, or a standard surveillance group receiving regular follow-ups and standard care. The UroAmp Test detects and monitors urothelial cancer risk potentially earlier than traditional methods, helping to tailor surveillance frequency.
During the study, participants will be monitored for up to 24 months with assessments including the number of cystoscopies performed, event-free survival, recurrence-free survival, and patient-reported outcomes. The study will track these measures to evaluate how well urine tumor DNA can guide surveillance intensity. Safety and overall health will be observed throughout the trial period.
CONDITIONS
Brief Title
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Research Team
L
Linda Topjian
C
Colette Osborne
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
UroAmp genomic urine test
Standard surveillance (cystoscopy)
What it is
A next‑generation sequencing based urine test (UroAmp) that detects DNA mutations associated with urothelial carcinoma for surveillance purposes
Standard diagnostic surveillance using periodic cystoscopy (and cytology as indicated) to monitor for recurrence in NMIBC
Role in trial
Investigational surveillance tool evaluated in the randomized arms
Comparator arm consisting of standard cystoscopy‑based surveillance
Primary use
Surveillance after initial therapy to detect recurrence or guide surveillance intensity
Monitoring for tumor recurrence through direct visualization and cytology
How it is performed
Done by collecting a urine sample and analyzing it via sequencing to detect tumor DNA
Periodic cystoscopic examination of the bladder with urine cytology when needed
Evidence status
Validation shows high sensitivity (~95%) and specificity (~90%) for diagnosis, with NPV about 99% for initial detection and promising prediction of recurrence risk
Cystoscopy remains the proven surveillance method endorsed by guidelines for recurrence detection
Important risks
Minimal physical risk as it is non‑invasive urine sampling
Invasive procedure with discomfort and potential complications from cystoscopy
Important limitations
Evidence derives from diagnostic validation and case‑control data; prospective clinical performance in reducing cystoscopy frequency not yet established
Invasive, resource‑intensive, may cause patient discomfort and procedure burden
Patient impact
Potential to reduce frequency of invasive cystoscopy, improving patient comfort and convenience
Reliable detection of recurrence but carries physical burden and inconvenience due to repeated procedures
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Diagnosed with high-risk non-muscle invasive bladder cancer
Completed induction treatment with BCG or gemcitabine/docetaxel
Negative initial post-induction therapy assessment (negative cytology and cystoscopy with or without biopsy)
You will not qualify if you...
High-risk non-muscle invasive bladder cancer within the past 3 years
Previous induction intravesical therapy
Variant histology present
Concurrent upper tract disease
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit for eligibility assessment
Treatment
Duration - Up to 24 months
Participants are randomly assigned to either less frequent cystoscopy surveillance guided by the UroAmp Test or standard surveillance with regular cystoscopy.
Regular follow-up visits as scheduled
Follow-up
Duration - Up to 24 months
Researchers monitor participants' event-free survival, recurrence-free survival, and patient-reported outcomes during and after surveillance.
Scheduled visits to assess outcomes
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Phase 1 Study Evaluating Safety and Pharmacokinetics of Intravesical UGN-501 in Adults with Recurrent Non-Muscle Invasive Bladder Cancer
A Phase III Study Evaluating Safety and Effectiveness of Intravesical FL115 Alone or With BCG in Treating Non-Muscle Invasive Bladder Cancer
Randomized Study Evaluating Alpha1H Before Surgery Compared to Standard Care in Adults with Low- to Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
Comparing Bladder-Sparing Therapies and Surgery for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer A Patient and Caregiver Observational Study
Study of Intravesical Gemcitabine and Docetaxel for Adults with High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Evaluating Effectiveness and Safety of Weekly and Monthly Bladder Treatments as an Alternative to Surgery
Study of LCS103 Herbal Formula with Standard Care to Prevent Recurrence of Non-Muscle Invasive Bladder Cancer
Evaluating Urine Tumor DNA Using the UroAmp Test to Reduce Cystoscopy Frequency for High-Risk Non-Muscle Invasive Bladder Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.